TY - JOUR
T1 - Genetische variaties beïnvloeden effectiviteit en veiligheid van geneesmiddelen
AU - Harmsze, Ankie M.
AU - Deneer, Vera H.
AU - Maitland-van Der Zee, Anke Hilse
AU - De Boer, Anthonius
AU - Klungel, Olaf H.
PY - 2010
Y1 - 2010
N2 - Pharmacogenetics is a field that deals with the relationship between genetic variations and the effects and side-effects of drugs. Genetic variations in drug-metabolizing enzymes, transporters, receptors, and other drug targets have been linked to interindividual differences in the efficacy and safety of many drugs. Genotyping is performed increasingly in primary and secondary health care in patients with abnormal plasma drug levels, in insufficient efficacy or in the presence of side-effects. Trastuzumab and abacavir are examples of drugs where patients are tested before treatment is started, in order to ascertain whether they carry a particular genetic variant. Trastuzumab is effective only when a particular protein is expressed in breast cancer tissue and the AIDS inhibitor may cause serious hypersensitivity reactions in patients carrying a particular variant. It is expected that screening for genetic variants prior to drug treatment will occur more often. This depends on the intensity of the association between genotype and outcome, the severity or relevance of the clinical outcome and the availability of alternative treatment
AB - Pharmacogenetics is a field that deals with the relationship between genetic variations and the effects and side-effects of drugs. Genetic variations in drug-metabolizing enzymes, transporters, receptors, and other drug targets have been linked to interindividual differences in the efficacy and safety of many drugs. Genotyping is performed increasingly in primary and secondary health care in patients with abnormal plasma drug levels, in insufficient efficacy or in the presence of side-effects. Trastuzumab and abacavir are examples of drugs where patients are tested before treatment is started, in order to ascertain whether they carry a particular genetic variant. Trastuzumab is effective only when a particular protein is expressed in breast cancer tissue and the AIDS inhibitor may cause serious hypersensitivity reactions in patients carrying a particular variant. It is expected that screening for genetic variants prior to drug treatment will occur more often. This depends on the intensity of the association between genotype and outcome, the severity or relevance of the clinical outcome and the availability of alternative treatment
UR - http://www.scopus.com/inward/record.url?scp=77954949803&partnerID=8YFLogxK
M3 - Article
C2 - 20699026
SN - 0028-2162
VL - 154
SP - 1329
EP - 1333
JO - Nederlands tijdschrift voor geneeskunde
JF - Nederlands tijdschrift voor geneeskunde
IS - 28
M1 - A1503
ER -